In November 2006 the Expert Advisory Committee on Drugs (EACD) recommended to Hon Jim Anderton, Associate Minister of Health, that Benzylpiperazine (BZP) and all known analogues and derivatives, be classified as Class C1 drugs under the Misuse of Drugs Act 1975.
In January 2007, Mr Anderton invited interested parties (manufacturers, retailers, researchers, users, health agencies, health professionals and others) to comment on the EACD proposal. It is intended that this comment feed into Mr Anderton’s decision-making on the proposed classification of the substances.
Sixty-four submissions were received, from a wide range of agencies and individuals, 61 in total.
This report comprises a detailed database summarising key points made by submitters, alongside summaries of research papers provided with submissions. The report also provides a brief overview of the submissions, pulling out key themes and views and, where they exist, presenting commonalities within and between different groups of agencies and individuals.